324 related articles for article (PubMed ID: 31033480)
21. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer.
Rahman MM; van Oosterom F; Enow JA; Hossain M; Gutierrez-Jensen AD; Cashen M; Everts A; Lowe K; Kilbourne J; Daggett-Vondras J; Karr TL; McFadden G
Cancer Res Commun; 2023 Jun; 3(6):952-968. PubMed ID: 37377603
[TBL] [Abstract][Full Text] [Related]
22. Targeting gallbladder carcinoma: bone marrow-derived stem cells as therapeutic delivery vehicles of myxoma virus.
Weng M; Zhang M; Qin Y; Gong W; Tang Z; Quan Z; Wu K
Chin Med J (Engl); 2014; 127(12):2350-6. PubMed ID: 24931255
[TBL] [Abstract][Full Text] [Related]
23. Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.
Ashton LV; Quackenbush SL; Castle J; Wilson G; McCoy J; Jordan M; MacNeill AL
Viruses; 2020 May; 12(5):. PubMed ID: 32397134
[TBL] [Abstract][Full Text] [Related]
24. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
[TBL] [Abstract][Full Text] [Related]
25. Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
Zhao Q; Tong J; Liu X; Li S; Chen D; Miao L
J Cancer Res Clin Oncol; 2022 May; 148(5):1269-1273. PubMed ID: 35212817
[TBL] [Abstract][Full Text] [Related]
26. The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing
De S; Lindner DJ; Coleman CJ; Wildey G; Dowlati A; Stark GR
Cancer Res; 2018 May; 78(9):2396-2406. PubMed ID: 29440145
[TBL] [Abstract][Full Text] [Related]
27. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
[TBL] [Abstract][Full Text] [Related]
28. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
[TBL] [Abstract][Full Text] [Related]
30. RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells.
Rahman MM; Gutierrez-Jensen AD; Glenn HL; Abrantes M; Moussatche N; McFadden G
J Virol; 2021 Jun; 95(14):e0015121. PubMed ID: 33952639
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
32. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR
Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246
[TBL] [Abstract][Full Text] [Related]
33. Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma.
Jazowiecka-Rakus J; Sochanik A; Rusin A; Hadryś A; Fidyk W; Villa N; Rahman MM; Chmielik E; Franco LS; McFadden G
Mol Ther Oncolytics; 2020 Sep; 18():335-350. PubMed ID: 32775618
[TBL] [Abstract][Full Text] [Related]
34. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
[TBL] [Abstract][Full Text] [Related]
35. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
36. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
37. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.
Doty RA; Liu J; McFadden G; Roy EJ; MacNeill AL
Oncolytic Virother; 2013 Jan; 2():1-17. PubMed ID: 25866742
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic Virotherapy with Myxoma Virus.
Rahman MM; McFadden G
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936317
[TBL] [Abstract][Full Text] [Related]
39. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo.
Meng S; Zhou Z; Chen F; Kong X; Liu H; Jiang K; Liu W; Hu M; Zhang X; Ding C; Wu Y
Cancer Lett; 2012 Apr; 317(1):56-64. PubMed ID: 22095029
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for thoracic oncology gone viral.
Patel MR
Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
